Chronic Myelomonocytic Leukemia Recruiting Phase 2 Trials for Enasidenib (DB13874)

Also known as: Chronic myelomonocytic leukaemia / Chronic myelomonocytic leukemia with failed remission / Leukemia, Myelomonocytic, Chronic

IndicationStatusPhase
DBCOND0028572 (Chronic Myelomonocytic Leukemia)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03683433Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationTreatment